A study showed that the CXCR4 antagonist Plerixafor mobilizes leukemia cells, thereby leading to sensitization of cytotoxic therapy and improvement of hematopoietic cell transplantation (HCT) [72]. The gene discussed is CXCR4; the disease is leukemia.